GO:0070006 metalloaminopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070006 metalloaminopeptidase activity describes the metal-dependent hydrolysis of the N-terminal amino acid from a polypeptide chain, using one or two metal ions to activate a water nucleophile.
• These enzymes are validated drug targets in malaria, where selective inhibitors of the Plasmodium M1 alanyl aminopeptidase block parasite growth.
• Metalloaminopeptidase inhibitors also prevent Cryptosporidium parvum excystation, highlighting their potential against apicomplexan parasites.
• In Porphyromonas gingivalis, gingipain-associated aminopeptidase activities contribute to periodontal tissue destruction and are linked to Alzheimer's disease pathology.
• Bestatin-based and amino-hydroxy-benzocycloheptenone inhibitors provide chemical probes to dissect metalloaminopeptidase function and therapeutic potential.
• CRISPR knockout, point-mutation, and knock-in models enable causal testing of metalloaminopeptidase genes in disease and drug-response studies.
Description
Metalloaminopeptidases are a class of proteolytic enzymes that remove N-terminal amino acids from peptides and proteins in a metal-dependent manner. The Gene Ontology term GO:0070006, metalloaminopeptidase activity, captures this molecular function, which is defined by a catalytic mechanism where one or two metal ions position a water molecule for nucleophilic attack on the peptide bond, while charged amino acid side chains serve as metal ligands. This activity is essential for protein maturation, peptide hormone processing, and antigen presentation, and it is widely distributed across prokaryotes and eukaryotes. Research into metalloaminopeptidases has accelerated because of their roles in infectious disease and cancer. For example, the Plasmodium falciparum M1 alanyl aminopeptidase is essential for hemoglobin digestion and has been chemically validated as an antimalarial target using selective inhibitors. In the apicomplexan parasite Cryptosporidium parvum, metalloaminopeptidase inhibitors block excystation, suggesting a role in host invasion. In the oral pathogen Porphyromonas gingivalis, gingipain-associated aminopeptidase activities degrade host peptides and contribute to periodontal disease, with links to Alzheimer's disease. Understanding GO:0070006 at the molecular level informs drug discovery and functional genomics. Structural and mechanistic studies of processive metalloaminopeptidases have revealed how these enzymes achieve processive degradation of peptide substrates. Inhibitor development has produced potent, selective compounds such as bestatin derivatives and dinuclear zinc inhibitors that serve as tool molecules and therapeutic leads. This article reviews the definition, mechanism, key genes, disease relevance, and research methods for metalloaminopeptidase activity, with a focus on how CRISPR-based models can advance the field.
metalloaminopeptidase activity At A Glance
| GO ID | GO:0070006 |
|---|---|
| GO term | metalloaminopeptidase activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. |
| Major function | Removal of N-terminal amino acids from peptides and proteins in a metal-dependent manner |
| Metal cofactors | Typically zinc or cobalt; some enzymes use dinuclear metal centers |
| Representative enzymes | M1 alanyl aminopeptidase, leucyl aminopeptidase, methionine aminopeptidase, aminopeptidase N |
| Inhibitor classes | Bestatin-based inhibitors, amino-hydroxy-benzocycloheptenones, hydroxamic acids |
What Is GO:0070006?
GO:0070006 metalloaminopeptidase activity is defined as the catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. In simpler terms, these enzymes use metal ions to activate water and clip off the first amino acid of a protein or peptide. This activity is distinct from endopeptidases, which cleave internal peptide bonds, and from non-metal-dependent aminopeptidases.
Why Is metalloaminopeptidase activity Important in Cell Biology?
Metalloaminopeptidase activity is important because it controls protein stability, peptide hormone processing, and nutrient acquisition in pathogens, making it a validated target for anti-infective and anticancer therapies. The essentiality of the Plasmodium M1 alanyl aminopeptidase for parasite survival and its chemical validation as a drug target underscore the therapeutic potential of inhibiting this activity. In addition, metalloaminopeptidases contribute to host-pathogen interactions in periodontal disease and potentially in neurodegeneration. Understanding their mechanism and regulation is therefore critical for drug discovery and for interpreting genetic variants that alter enzyme function.
• Validated antimalarial target: Plasmodium M1 alanyl aminopeptidase is essential and selectively inhibited by bestatin-based compounds.
• Cryptosporidiosis: metalloaminopeptidase inhibitors prevent Cryptosporidium parvum excystation in vitro.
• Periodontal disease: Porphyromonas gingivalis gingipain aminopeptidase activities degrade host peptides and contribute to tissue destruction.
• Cancer: aminopeptidase N (CD13) is overexpressed in some tumors and is a target for bestatin-based inhibitors.
• Protein maturation: methionine aminopeptidases remove initiator methionine, affecting protein stability and localization.
• Drug discovery: diverse inhibitor scaffolds (bestatin, benzocycloheptenones) provide tool compounds and leads.
• Mechanistic enzymology: processive metalloaminopeptidases serve as models for metal-dependent catalysis.
• Chemical proteomics: activity-based probes enable selective target engagement studies in parasites.
• Host-pathogen interactions: pathogen aminopeptidases modulate host immune responses and tissue invasion.
• Genetic validation: CRISPR knockout of metalloaminopeptidase genes can confirm essentiality and guide drug development.
Molecular Mechanism of metalloaminopeptidase activity
Substrate recognition and binding
In simple terms: The enzyme grabs the end of a protein chain and positions the first amino acid for cutting.
Metalloaminopeptidases recognize the N-terminus of polypeptide substrates through a conserved active site that accommodates the free alpha-amino group. The S1 pocket determines specificity for the N-terminal residue, as shown by structural studies of the malaria M1 alanyl aminopeptidase with bestatin-based inhibitors. Processive enzymes can sequentially remove multiple residues without releasing the substrate, as demonstrated for a processive metalloaminopeptidase.
Metal ion coordination and water activation
In simple terms: Metal ions hold a water molecule and make it reactive so it can break the peptide bond.
The catalytic mechanism relies on one or two metal ions, typically zinc or cobalt, that are coordinated by conserved histidine, glutamate, and aspartate residues. These metal ions polarize a water molecule, lowering its pKa and enabling nucleophilic attack on the scissile peptide bond. Dinuclear zinc centers are characteristic of many metalloaminopeptidases and are targeted by inhibitors such as amino-hydroxy-benzocycloheptenones.
Catalysis and product release
In simple terms: The enzyme cuts off the first amino acid and releases it, then moves on to the next one.
Following nucleophilic attack, the peptide bond is cleaved, releasing the N-terminal amino acid and a shortened peptide. For processive enzymes, the shortened peptide remains bound and is further degraded, as shown by kinetic and structural analyses. The reaction is metal-dependent, and chelating agents abolish activity, confirming the essential role of the metal ions.
Inhibition by small molecules
In simple terms: Drug-like molecules can block the enzyme by mimicking the substrate or binding to the metal center.
Bestatin and its derivatives are transition-state analogs that bind to the active site and inhibit metalloaminopeptidases. Amino-hydroxy-benzocycloheptenones act as potent, selective, non-peptidic dinuclear zinc inhibitors. These inhibitors have been used to validate the Plasmodium M1 alanyl aminopeptidase as a drug target and to block Cryptosporidium excystation.
Key Genes Involved in GO:0070006 metalloaminopeptidase activity
The following genes encode enzymes that exhibit metalloaminopeptidase activity (GO:0070006) or are directly involved in its regulation and inhibition.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANPEP (CD13) | Membrane alanyl aminopeptidase | Cancer target; bestatin inhibitor studies |
| LNPEP | Leucyl-cystinyl aminopeptidase | Peptide hormone processing; insulin-regulated |
| METAP1 | Methionine aminopeptidase 1 | Protein N-terminal maturation; inhibitor target |
| METAP2 | Methionine aminopeptidase 2 | Angiogenesis inhibitor target; fumagillin binding |
| PF3D7_1311800 (M1 AAP) | Plasmodium falciparum M1 alanyl aminopeptidase | Validated antimalarial target |
| ERAP1 | Endoplasmic reticulum aminopeptidase 1 | Antigen presentation; autoimmune disease associations |
| ERAP2 | Endoplasmic reticulum aminopeptidase 2 | Antigen processing; inflammatory disease |
| NPEPPS | Puromycin-sensitive aminopeptidase | Neurodegeneration; tau clearance |
| RNPEP | Arginyl aminopeptidase | Peptide processing; cardiovascular biology |
| XPNPEP1 | X-prolyl aminopeptidase 1 | Proline-specific cleavage; hypertension |
| LAP3 | Leucine aminopeptidase 3 | Cancer biomarker; immune regulation |
| CPQ | Carboxypeptidase Q | Peptide trimming; bone metabolism |
| PGP (gingipain) | Porphyromonas gingivalis gingipain aminopeptidase | Periodontal disease; Alzheimer's link |
| Cryptosporidium CpAAP | Cryptosporidium parvum aminopeptidase | Excystation; parasite invasion |
| BEST1 | Bestrophin 1 (not an aminopeptidase) | Not applicable; included for clarity |
| M1 family members | Various M1 metalloaminopeptidases | Broad substrate specificity; drug targets |
| Aminopeptidase N homologs | Bacterial and parasitic enzymes | Antibiotic and antiparasitic targets |
How Is metalloaminopeptidase activity Regulated?
Metalloaminopeptidase activity is regulated at multiple levels. Expression of specific enzymes can be induced by physiological cues, such as insulin-regulated aminopeptidase (LNPEP) in glucose transport. In pathogens, enzyme activity may be controlled by zymogen activation or compartmentalization. Inhibitor proteins and small molecules can modulate activity; for example, bestatin and its derivatives inhibit M1 alanyl aminopeptidase. Metal ion availability also influences catalysis, as the enzymes require zinc or cobalt for activity. Additionally, post-translational modifications and proteolytic processing can affect enzyme localization and function.
metalloaminopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PF3D7_1311800 (M1 AAP) | Malaria | Plasmodium knockout or point-mutation parasites; inhibitor assays |
| ANPEP (CD13) | Cancer, angiogenesis | Cancer cell line knockout; xenograft models |
| PGP (gingipain) | Periodontal disease, Alzheimer's disease | P. gingivalis infection models; gingipain knockout strains |
| Cryptosporidium CpAAP | Cryptosporidiosis | In vitro excystation assays with inhibitors |
| ERAP1 | Autoimmune diseases | ERAP1 knockout mice; antigen presentation assays |
Malaria
The Plasmodium falciparum M1 alanyl aminopeptidase is essential for hemoglobin digestion and parasite survival. Selective inhibitors, including bestatin-based compounds, block enzyme activity and parasite growth, validating it as an antimalarial target. Chemoproteomics has confirmed selective target engagement in live parasites.
Cryptosporidiosis
Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation, a critical step for host infection. This suggests that targeting metalloaminopeptidase activity could be a therapeutic strategy against cryptosporidiosis.
Periodontal disease and Alzheimer's disease
Porphyromonas gingivalis gingipain-associated aminopeptidase activities degrade host peptides and contribute to periodontal tissue destruction. These activities have also been linked to Alzheimer's disease pathology, possibly through systemic inflammation or direct neurotoxic effects.
Cancer
Aminopeptidase N (CD13) is overexpressed in various cancers and promotes angiogenesis and tumor invasion. Bestatin, a metalloaminopeptidase inhibitor, has been investigated as an anticancer agent. Other metalloaminopeptidases, such as leucine aminopeptidase 3, are potential biomarkers.
From metalloaminopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the metalloaminopeptidase gene essential for pathogen survival? | CRISPR knockout in Plasmodium or Cryptosporidium |
| Does a point mutation in the active site abolish catalytic activity? | CRISPR point mutation (e.g., metal-ligand residue) in cell lines |
| Can a disease-associated variant alter substrate specificity? | Knock-in of mutant allele in isogenic cell lines |
| Where is the enzyme localized in cells? | Tagged knock-in with fluorescent protein |
| Does overexpression of the enzyme promote cancer cell proliferation? | Overexpression in cancer cell lines |
| Can chemical inhibitors selectively engage the target in live cells? | Chemoproteomics with activity-based probes |
How to Study the metalloaminopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Chromogenic/fluorogenic substrate assays | Enzymatic activity and kinetics | Inhibitor screening, enzyme characterization |
| X-ray crystallography | Three-dimensional structure | Active site mapping, inhibitor design |
| Chemoproteomics | Target engagement in live cells | Drug target validation |
| CRISPR knockout | Gene essentiality and loss-of-function phenotypes | Pathogen and cancer models |
| CRISPR point mutation | Catalytic residue function | Mechanistic enzymology |
| Knock-in tagging | Subcellular localization | Imaging studies |
| Overexpression | Gain-of-function effects | Cancer and signaling studies |
| RNA-seq | Transcriptional changes upon perturbation | Pathway analysis |
Enzymatic activity assays
Metalloaminopeptidase activity is commonly measured using chromogenic or fluorogenic substrates, such as Leu-p-nitroanilide or Ala-AMC. These assays can be performed with purified enzyme or cell lysates and are used to determine kinetic parameters and inhibitor potency. Metal chelators are used to confirm metal dependence.
Structural biology
X-ray crystallography and cryo-EM provide atomic-level insights into substrate binding and catalysis. Structures of the malaria M1 alanyl aminopeptidase with bestatin-based inhibitors revealed the S1 pocket and binding mode. Processive metalloaminopeptidase structures have elucidated mechanisms of processivity.
Chemical proteomics
Activity-based probes and chemoproteomics enable selective target engagement studies in complex proteomes. This approach validated the Plasmodium M1 alanyl aminopeptidase as a druggable target and identified off-targets.
CRISPR-based functional genomics
CRISPR knockout, point mutation, and knock-in models allow causal testing of metalloaminopeptidase genes. For example, knockout of the Plasmodium M1 alanyl aminopeptidase gene can confirm essentiality, while point mutations can dissect catalytic residues. These models are complemented by overexpression and tagged knock-in for localization studies.
How CRISPR Can Be Used to Study GO:0070006 metalloaminopeptidase activity
Knockout
CRISPR knockout of metalloaminopeptidase genes can confirm essentiality in pathogens such as Plasmodium and Cryptosporidium. In cancer cell lines, knockout of ANPEP (CD13) can reduce proliferation and angiogenesis, validating it as a target. Knockout models are also used to study substrate processing and downstream signaling.
Point Mutation
Point mutations in metal-coordinating residues (e.g., histidine, glutamate) can abolish catalytic activity without affecting protein stability. CRISPR-mediated point mutation allows precise dissection of the catalytic mechanism and metal dependence. Such models are valuable for testing whether specific residues are required for substrate binding or catalysis.
Knock-in
Knock-in of disease-associated variants or tagged versions of metalloaminopeptidases enables studies of localization, trafficking, and function. For example, fluorescent tagging of the endogenous gene allows real-time imaging of enzyme dynamics. Knock-in of mutant alleles can model human genetic disorders linked to aminopeptidase dysfunction.
Overexpression
Overexpression of metalloaminopeptidases in cell lines can mimic pathological states such as cancer, where ANPEP is overexpressed. Overexpression models are used to study downstream effects on cell proliferation, migration, and invasion, and to test inhibitor efficacy in a gain-of-function context.
How EDITGENE Supports metalloaminopeptidase activity Research
Researchers studying metalloaminopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in a disease or pathway. EDITGENE provides CRISPR-based cell models and screening services to accelerate this functional validation.
Contact EDITGENE today to design your custom CRISPR model for metalloaminopeptidase activity research.
Frequently Asked Questions About metalloaminopeptidase activity
What is metalloaminopeptidase activity?
Metalloaminopeptidase activity (GO:0070006) is the metal-dependent hydrolysis of the N-terminal amino acid from a polypeptide chain, using one or two metal ions to activate a water molecule.
What genes are involved in metalloaminopeptidase activity?
Key genes include ANPEP (CD13), LNPEP, METAP1, METAP2, ERAP1, ERAP2, NPEPPS, and the Plasmodium M1 alanyl aminopeptidase gene PF3D7_1311800.
How is metalloaminopeptidase activity regulated?
It is regulated by metal ion availability, substrate availability, post-translational modifications, and inhibitor proteins; small-molecule inhibitors such as bestatin can block activity.
What diseases are associated with metalloaminopeptidase activity?
Malaria, cryptosporidiosis, periodontal disease, Alzheimer's disease, and cancer have been linked to metalloaminopeptidase activity.
What are the inhibitors of metalloaminopeptidases?
Bestatin and its derivatives, amino-hydroxy-benzocycloheptenones, and hydroxamic acids are common inhibitors.
How can I study metalloaminopeptidase activity in the lab?
Use chromogenic or fluorogenic substrate assays, structural biology, chemoproteomics, and CRISPR knockout or point mutation models.
What is the role of metal ions in metalloaminopeptidase activity?
Metal ions, typically zinc or cobalt, hold the water molecule in place and stabilize the transition state during catalysis.
Can CRISPR be used to study metalloaminopeptidase genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of gene function in disease and drug response.
What is the Plasmodium M1 alanyl aminopeptidase?
It is an essential metalloaminopeptidase in Plasmodium falciparum that digests hemoglobin and is a validated antimalarial drug target.
How does EDITGENE support metalloaminopeptidase research?
EDITGENE provides custom CRISPR cell models, library screening, and bioinformatics to study metalloaminopeptidase genes and their role in disease.
Conclusion
GO:0070006 metalloaminopeptidase activity defines a fundamental enzymatic function that is essential for protein processing and pathogen survival. Its role in malaria, cryptosporidiosis, periodontal disease, and cancer has made it a focus of drug discovery, with multiple inhibitor classes and validated targets. Mechanistic studies continue to reveal how metal ions and active-site residues drive catalysis and processivity. CRISPR-based models are powerful tools to dissect the genetic and molecular basis of metalloaminopeptidase function. By combining knockout, point mutation, knock-in, and overexpression approaches with biochemical and proteomic methods, researchers can accelerate the translation of these findings into new therapies.
References
- 1. Simpson MC et al.. 2023. Unveiling the Catalytic Mechanism of a Processive Metalloaminopeptidase.. Biochemistry 62(22):3188-3205 PMID: 37924287
- 2. Mucha A et al.. 2010. Metallo-aminopeptidase inhibitors.. Biochimie 92(11):1509-29 PMID: 20457213
- 3. Al-Lakkis-Wehbe M et al.. 2013. Synthesis of amino-hydroxy-benzocycloheptenones as potent, selective, non-peptidic dinuclear zinc metalloaminopeptidase inhibitors.. Bioorg Med Chem 21(21):6447-55 PMID: 24055078
- 4. Okhuysen PC et al.. 1996. Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation.. Antimicrob Agents Chemother 40(12):2781-4 PMID: 9124840
- 5. Giannangelo C et al.. 2024. Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy.. Elife 13 PMID: 38976500
- 6. Creek D et al.. 2024. Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy.. Res Sq PMID: 38746424
- 7. Velmourougane G et al.. 2011. Synthesis of new (-)-bestatin-based inhibitor libraries reveals a novel binding mode in the S1 pocket of the essential malaria M1 metalloaminopeptidase.. J Med Chem 54(6):1655-66 PMID: 21366301
- 8. Veillard F et al.. 2012. Gingipain aminopeptidase activities in Porphyromonas gingivalis.. Biol Chem 393(12):1471-6 PMID: 23667904
